Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GlaxoSmithKline

GSK Glaxo Smith clinical programs — 86 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

GSK Glaxo Smith projects

86 ClinicalTrials.gov programs sponsored by GSK Glaxo Smith.

GSK Glaxo Smith has 86 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

86 programs

Clinical programs

Page 1 of 2

  1. 104317

    GlaxoSmithKline

    Hypereosinophilic Syndrome

    phase 3 other active

    1 trial

  2. 206785

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 small molecule active

    1 trial

  3. 207495

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. 207499

    GlaxoSmithKline

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  5. 207503

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  6. 212496

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  7. 212895

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  8. 213400

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  9. 213410

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  10. 213823

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  11. 213997 (VNS 20-001)

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  12. 213998 (VNS 20-002)

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  13. 214002 (VNS 20-004)

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  14. 214828

    GlaxoSmithKline

    Multiple myeloma

    phase 3 small molecule active

    1 trial

  15. 217013

    GlaxoSmithKline

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  16. 217102

    GlaxoSmithKline

    Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy

    phase 3 small molecule active

    1 trial

  17. 217848

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  18. 218224

    GlaxoSmithKline

    systemic sclerosis associated interstitial lung disease

    phase 3 small molecule active

    1 trial

  19. 220030

    GlaxoSmithKline

    Invasive meningococcal disease (IMD)

    phase 3 small molecule active

    1 trial

  20. 220735

    GlaxoSmithKline

    Asthma

    phase 3 small molecule active

    1 trial

  21. 221530

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  22. 221672

    GlaxoSmithKline

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  23. 222090

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  24. 222253

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  25. 222725

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  26. 223105

    GlaxoSmithKline

    Varicella

    phase 3 small molecule active

    1 trial

  27. 223529

    GlaxoSmithKline

    Asthma with type 2 inflammation characterized by an eosinophilic phenotype

    phase 3 other active

    1 trial

  28. 223674

    GlaxoSmithKline

    Neoplasms, Lung

    phase 3 small molecule active

    1 trial

  29. 224295

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  30. Belantamab mafodotin

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  31. Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline

    connective tissue diseases

    phase 3 small molecule active

    1 trial

  32. Bepirovirsen

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

  33. Cervarix™

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial

  34. Dostarlimab

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  35. Eltrombopag

    GlaxoSmithKline

    Non-alcoholic Steatohepatitis

    phase 3 small molecule terminated

    1 trial

  36. FF

    GlaxoSmithKline

    Rhinitis, Allergic, Perennial

    phase 3 small molecule completed

    1 trial

  37. FF/GW642444 Inhalation Powder

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 3 small molecule completed

    2 trials

  38. FF/UMEC/VI

    GlaxoSmithKline

    Asthma

    phase 3 small molecule active

    1 trial

  39. FluLaval® Quadrivalent

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  40. Fluticasone furoate

    GlaxoSmithKline

    Rhinitis

    phase 3 small molecule completed

    1 trial

  41. GSK 2132231A

    GlaxoSmithKline

    Melanoma

    phase 3 small molecule terminated

    1 trial

  42. GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)

    GlaxoSmithKline

    Influenza

    phase 3 mab completed

    1 trial

  43. GSK1605786A

    GlaxoSmithKline

    Crohn's Disease

    phase 3 small molecule terminated

    2 trials

  44. GSK2118436

    GlaxoSmithKline

    Cancer

    phase 3 small molecule completed

    1 trial

  45. GSK2585823(CLDM 1%-BPO 3% gel)

    GlaxoSmithKline

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  46. GSK3196165 (Otilimab)

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 3 mab completed

    1 trial

  47. GW406381

    GlaxoSmithKline

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  48. GW685698/GW642444

    GlaxoSmithKline

    Asthma

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does GSK Glaxo Smith have?

86 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.